OraSure Technologies, Inc. (OSUR)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$3.48-2.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Intact: The reason to own it still holds.
OraSure aims to grow revenue in diagnostics to about $28.5 million next quarter. The company targets gross margins near 40% in the same period. Recent M&A activity and share buyback plans show management commitment. These moves could help stabilize and improve the business.
OraSure is currently loss-making with negative free cash flow. Analysts expect EPS losses near $0.7 for 2026. Revenue growth is modest and guidance is mixed. Key leadership departures and earnings misses raise concerns about execution.
The market expects about 9% revenue growth next year and some improvement in results. Our view is cautious given the company’s ongoing losses and execution risks. The stock price reflects typical valuation for peers but with elevated risk.
Breaks if: Gross margin falls below 35% next quarter
Breaks if: No progress on commercialization or M&A by end of 2026
Revenue falls below $27 million next quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the healthcare sector. The company is currently loss-making but is focusing on revenue growth and operational efficiency, which could support a positive trajectory over the next few years.
The market appears to have priced in a low expectations gap, indicating that investors may not be anticipating significant improvements. OSUR is seen as cheap compared to its peers, but the valuation reflects the risks associated with its recent earnings misses.
Management is on track with priorities to drive revenue growth and improve gross margins. However, the company has a history of earnings misses, which adds some near-term risk to its performance.
The long-term thesis hinges on the company's ability to meet or exceed guidance in upcoming earnings calls. Additionally, the performance of larger healthcare companies may influence OSUR's momentum positively or negatively.
The most important moves since the prior daily snapshot.
Confidence changed from 'medium' to 'high'.
Mixed, the news cuts both ways. Revenue growth in the diagnostics industry supports the read. However, growth concerns persist despite returning to profitability.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on building momentum in the diagnostics industry for revenue growth in 2026 and beyond.
Over the next 1 to 3 years, OSUR's success will depend on its execution of growth strategies and the broader healthcare sector's performance. Not investment advice.